1. von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Resp Crit Care Med . 2008;177:1026-1032.
2. Thoma J, Gunten CV. Dyspnea. In: Bruera E, Higginson IJ, Ripamonti C, et al, eds. Textbook of Palliative Medicine . London: Hodder Arnold; 2009.
3. Manning H, Schwartzstein R. Pathophysiology of dyspnea. N Engl J Med . 1995;333;1547-1553.
4. O’Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med . 1997;155:530-535.
5. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis . 1993;148:1351-1357.
6. Seferovic PM, Ristic AD, Maksimovic R, et al. Pericardial syndromes: an update after the ESC guidelines 2004. Heart Fail Rev . 2013;18:255-266.
7. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation . 2014;130:1601-1606.
8. LeWinter MM. Acute pericarditis. N Engl J Med . 2014;371:2410-2416.
9. Pursnani A, Yee H, Slater W, et al. Hypersensitivity myocarditis associated with azithromycin exposure. Ann Intern Med . 2009;150:225-226.
10. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet . 2012;379:738-747.
11. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax . 2000;55:1000-1006.
12. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet . 2011;378:1949-1961.
13. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med . 2015;192:e3-e19.
14. Stringham R, Shah NR. Pulmonary arterial hypertension: an update on diagnosis and treatment. Am Fam Physician . 2010;82:370-377.
15. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlate and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med . 2000;161:487-492.
16. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest . 1997;112:714-721.
17. Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patient with sickle cell disease. Am J Hematol . 2010;85:36-40.
18. Martin CR, Johnson CS, Cobb C, et al. D. Myocardial infarction in sickle cell disease. J Natl Med Assoc . 1996;88:428-432.
19. Paul RN, Castro OL, Aggarwal A, et al. Acute chest syndrome: sickle cell disease. Eur J Haematol . 2011;87:191-207.
20. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med . 2011;364:1046-1060.
21. Crawford J, Cox EB, Cohen HJ. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med . 1985;79:13-22.
22. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol . 2012;32;215-226.
23. Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol . 2010;23:530-535.
24. Skeie GO, Mygland A, Aarli JA, et al. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity . 1995;20:99-104.
25. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord . 2006;16:459-467.
